Interaction Checker

Interaksi Pirfenidon

Pirfenidon (Esbriet) memiliki 12 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 11 mayor, 0 moderat, 0 minor, dan 1 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (11)

  • Deferasirokssuplemen zat besiMayor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (label Pirfenidon, Interaksi obat)

  • FluvoksaminSSRIMayor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (label Pirfenidon, Interaksi obat)

  • Kanabidiol (obat resep)antikonvulsanMayor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (label Pirfenidon, Interaksi obat)

  • KarbamazepinantikonvulsanMayor

    Therefore, discontinue use of strong CYP1A2 inducers prior to ESBRIET treatment and avoid the concomitant use of ESBRIET and a strong CYP1A2 inducer [see Clinical Pharmacology (12.3) ] . (label Pirfenidon, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralMayor

    Therefore, discontinue use of strong CYP1A2 inducers prior to ESBRIET treatment and avoid the concomitant use of ESBRIET and a strong CYP1A2 inducer [see Clinical Pharmacology (12.3) ] . (label Pirfenidon, Interaksi obat)

  • MeksiletinantiaritmiaMayor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (label Pirfenidon, Interaksi obat)

  • RitonavirantiretroviralMayor

    Therefore, discontinue use of strong CYP1A2 inducers prior to ESBRIET treatment and avoid the concomitant use of ESBRIET and a strong CYP1A2 inducer [see Clinical Pharmacology (12.3) ] . (label Pirfenidon, Interaksi obat)

  • Simetidinpenghambat H2Mayor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (label Pirfenidon, Interaksi obat)

  • SiprofloksasinfluorokuinolonMayor

    If ciprofloxacin at the dosage of 750 mg twice daily cannot be avoided, dosage reductions are recommended [see Dosage and Administration (2.4) ]. (label Pirfenidon, Interaksi obat)

  • Viloksazinpenghambat ambilan kembali norepinefrinMayor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (label Pirfenidon, Interaksi obat)

  • Zileutonpenghambat CYP1A2Mayor

    Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. (label Pirfenidon, Interaksi obat)

Tidak ada interaksi bermakna yang dilaporkan (1)

  • NintedanibTanpa interaksi

    Pirfenidone In a multiple-dose study conducted to assess the pharmacokinetic effects of concomitant treatment with nintedanib and pirfenidone, the coadministration of nintedanib with pirfenidone did not alter the exposure of either agent [see Clinical Pharmacology (12.3) ] . (label Nintedanib, Interaksi obat)

Periksa Pirfenidon terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.